Several global pharmaceutical firms have acknowledged that the bribery scandal in China has slowed sales, but their chief concern is whether it will affect business in such emerging markets as Brazil, Russia and India, where growth had been slowing before the bribery issue arose. One-third of Sanofi's revenue comes from emerging markets, compared to approximately 26% for Roche, GlaxoSmithKline and Novartis.

Full Story:

Related Summaries